Influence of hormone replacement therapy on c-reactive protein: Population-based data

European Journal of Preventive Cardiology

Volumn 10, Issue 1, 2003, Pages 57-60

  Primatesta, Paola ^a   Falaschetti, Emanuela ^a   Poulter, Neil R ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HORMONE;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CORONARY RISK; DRINKING BEHAVIOR; FEMALE; GROUPS BY AGE; HEALTH SURVEY; HORMONE SUBSTITUTION; HUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK REDUCTION; SMOKING; UNITED KINGDOM; CARDIOVASCULAR RISK; CONTROLLED STUDY; ISCHEMIC HEART DISEASE; NORMAL HUMAN; POPULATION;

ADULT; AGED; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; ENGLAND; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; REGRESSION ANALYSIS;

EID: 84992810673     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/174182670301000109     Document Type: Article

References (17)

1. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55–72.
2. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801–1811.
3. Mosca L. The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch Int Med 2000; 160: 14–28.
4. Barrett-Connor E. Hormone replacement therapy. BMJ 1998; 317: 457–461.
5. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613.
6. Whitehead M, Stampfer M. HERS: A missed opportunity. Climacteric 1998; 1: 170–171.
7. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials. BMJ 1997; 315: 149–153.
8. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345: 1243–1249.
9. Writing Group for the Women's Health Initiative Investigation. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321–333.
10. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ 2000; 321: 199–204.
11. Erens B, Primatesta P, (eds). The Health Survey for England 1998. Cardiovascular disease 1998. London: The Stationery Office; 1999.
12. Wilkins J, Gallimore JR, Moore E, Pepys MB. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem 1998; 44: 1358–1361.
13. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713–716.
14. Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999; 19: 893–899.
15. Barinas-Mitchell E, Cushman M, Meilahn EN, Tracy RP, Kuller LH. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. Am J Epidemiol 2001; 153: 1094–1101.
16. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al Effect of postmenopausal hormones on inflammation-sensitive proteins. The Postmenopausal Estrogen/Progestin Intervention (PEPI) Study. Circulation 1999; 100: 717–722.
17. Eidelman RS, Lamas GA, Hennekens CH, Ridker PM. Aspirin, postmenopausal hormones, and C-reactive protein. Arch Int Med 2002; 162: 480–481.